{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T06:11:08Z","timestamp":1788588668805,"version":"build-2803163510"},"reference-count":15,"publisher":"American Medical Association (AMA)","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Dermatol"],"published-print":{"date-parts":[[2024,7,1]]},"abstract":"<jats:sec id=\"ab-dbr240007-4\"><jats:title>Importance<\/jats:title><jats:p>Masculinizing gender-affirming hormonal therapy is associated with the development of acne. While isotretinoin is a highly effective acne treatment, little is known about its effectiveness and safety among transgender and gender-diverse individuals receiving gender-affirming hormonal therapy.<\/jats:p><\/jats:sec><jats:sec id=\"ab-dbr240007-5\"><jats:title>Objective<\/jats:title><jats:p>To evaluate clinical outcomes of isotretinoin among transgender and gender-diverse individuals receiving gender-affirming hormonal therapy.<\/jats:p><\/jats:sec><jats:sec id=\"ab-dbr240007-6\"><jats:title>Design, Setting, and Participants<\/jats:title><jats:p>This multicenter retrospective case series study was conducted at 4 medical centers: Mass General Brigham, University of Pennsylvania, Emory University, and Fenway Health. It included patients aged between 12 and 49 years who were receiving masculinizing gender-affirming hormonal therapy and prescribed isotretinoin for the management of acne between August 14, 2015, and September 20, 2023.<\/jats:p><\/jats:sec><jats:sec id=\"ab-dbr240007-7\"><jats:title>Exposure<\/jats:title><jats:p>Isotretinoin therapy for the management of acne.<\/jats:p><\/jats:sec><jats:sec id=\"ab-dbr240007-8\"><jats:title>Main Outcomes and Measures<\/jats:title><jats:p>The percentage of patients experiencing improvement or clearance of acne, as well as rates of acne recurrence. Adverse effects and reasons for treatment discontinuation were also evaluated.<\/jats:p><\/jats:sec><jats:sec id=\"ab-dbr240007-9\"><jats:title>Results<\/jats:title><jats:p>Among 55 included patients, the mean (SD) age was 25.4 years; 4 (7.3%) were Asian, 2 (3.6%) were Black, 4 (7.2%) were Hispanic, 1 was (1.8%) multiracial, and 36 (65.5%) were White. The median isotretinoin course duration was 6 months (IQR, 4.0-8.0), with a median cumulative dose of 132.7 mg\/kg (IQR, 66.4-168.5); the cumulative dose was less than 90 mg\/kg for 16 patients (29.1%) and less than 120 mg\/kg for 22 patients (40.0%). Isotretinoin was associated with improvement in 48 patients (87.3%) and clearance in 26 patients (47.3%). For the 33 patients treated with a cumulative dose of 120 mg\/kg or more, these rates increased to 32 patients (97.0%) and 21 patients (63.6%), respectively. Among the 20 patients who achieved acne clearance and had any subsequent health care encounters, the risk of recurrence was 20.0% (n\u2009=\u20094). The most frequently reported adverse effects were dryness (n\u2009=\u200944; 80.0%), joint pain (n\u2009=\u20098; 14.5%), and eczema (n\u2009=\u20095; 9.1%). Laboratory abnormalities were uncommon. Reasons for premature treatment discontinuation included cost, pharmacy issues, adverse effects, logistical reasons (scheduling), and wound healing concerns for gender-affirming surgery.<\/jats:p><\/jats:sec><jats:sec id=\"ab-dbr240007-10\"><jats:title>Conclusion and Relevance<\/jats:title><jats:p>In this case series study of individuals with acne who were receiving masculinizing gender-affirming hormonal therapy and underwent isotretinoin treatment, isotretinoin was often effective and well tolerated. However, premature treatment discontinuation was common and associated with poorer outcomes. Further efforts are needed to understand optimal dosing and treatment barriers to improve outcomes in transgender and gender-diverse individuals receiving masculinizing gender-affirming hormonal therapy.<\/jats:p><\/jats:sec>","DOI":"10.1001\/jamadermatol.2024.1420","type":"journal-article","created":{"date-parts":[[2024,5,29]],"date-time":"2024-05-29T15:00:40Z","timestamp":1716994840000},"page":"741","source":"Crossref","is-referenced-by-count":10,"title":["Isotretinoin for Acne in Transgender and Gender-Diverse Individuals Receiving Masculinizing Hormone Therapy"],"prefix":"10.1001","volume":"160","author":[{"given":"James","family":"Choe","sequence":"first","affiliation":[{"name":"Department of Dermatology, Brigham and Women\u2019s Hospital, Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Shields","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Brigham and Women\u2019s Hospital, Harvard Medical School, Boston, Massachusetts"},{"name":"Drexel University College of Medicine, Philadelphia, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alana","family":"Ferreira","sequence":"additional","affiliation":[{"name":"Perelman School of Medicine, University of Pennsylvania, Philadelphia,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Gold","sequence":"additional","affiliation":[{"name":"Emory University School of Medicine, Atlanta, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeromy W.","family":"Gotschall","sequence":"additional","affiliation":[{"name":"Perelman School of Medicine, University of Pennsylvania, Philadelphia,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kanika","family":"Kamal","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Brigham and Women\u2019s Hospital, Harvard Medical School, Boston, Massachusetts"},{"name":"Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Austin","family":"Rios","sequence":"additional","affiliation":[{"name":"The Fenway Institute, Fenway Health, Boston, Massachusetts"},{"name":"Department of Dermatology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robin H.","family":"Wang","sequence":"additional","affiliation":[{"name":"Perelman School of Medicine, University of Pennsylvania, Philadelphia,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily","family":"Baumrin","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Perelman School of Medicine, University of Pennsylvania, Philadelphia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erica D.","family":"Dommasch","sequence":"additional","affiliation":[{"name":"Harvard Medical School, Boston, Massachusetts"},{"name":"The Fenway Institute, Fenway Health, Boston, Massachusetts"},{"name":"Department of Dermatology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Howa","family":"Yeung","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Emory University School of Medicine, Atlanta, Georgia"},{"name":"Associate Editor, JAMA Dermatology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jules B.","family":"Lipoff","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Lewis Katz School of Medicine, Temple University, Philadelphia, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John S.","family":"Barbieri","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Brigham and Women\u2019s Hospital, Harvard Medical School, Boston, Massachusetts"},{"name":"Associate Editor, JAMA Dermatology"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"5","key":"dbr240007r2","doi-asserted-by":"publisher","first-page":"1450","DOI":"10.1016\/j.jaad.2020.02.053","article-title":"Prevalence of moderate to severe acne in transgender adults: a cross-sectional survey.","volume":"83","author":"Yeung","year":"2020","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"dbr240007r3","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1001\/jamadermatol.2020.5347","article-title":"Incidence and factors associated with acne among transgender patients receiving masculinizing hormone therapy.","volume":"157","author":"Thoreson","year":"2021","journal-title":"JAMA Dermatol"},{"issue":"1","key":"dbr240007r4","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1111\/jsm.12366","article-title":"Short- and long-term clinical skin effects of testosterone treatment in trans men.","volume":"11","author":"Wierckx","year":"2014","journal-title":"J Sex Med"},{"issue":"3","key":"dbr240007r5","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1001\/jamadermatol.2020.5353","article-title":"Moderate-to-severe acne and mental health symptoms in transmasculine persons who have received testosterone.","volume":"157","author":"Braun","year":"2021","journal-title":"JAMA Dermatol"},{"issue":"11","key":"dbr240007r6","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.1001\/jamadermatol.2015.0761","article-title":"Severe acne in female-to-male transgender patients.","volume":"151","author":"Turrion-Merino","year":"2015","journal-title":"JAMA Dermatol"},{"issue":"3","key":"dbr240007r7","doi-asserted-by":"publisher","first-page":"e155","DOI":"10.1111\/pde.2018.35.issue-3","article-title":"Transgender adolescents and acne: a cases series.","volume":"35","author":"Campos-Mu\u00f1oz","year":"2018","journal-title":"Pediatr Dermatol"},{"issue":"2","key":"dbr240007r8","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1016\/j.jaad.2016.03.019","article-title":"Standardized laboratory monitoring with use of isotretinoin in acne.","volume":"75","author":"Hansen","year":"2016","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"dbr240007r9","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1111\/ijd.2016.55.issue-5","article-title":"Making sense of the effects of the cumulative dose of isotretinoin in acne vulgaris.","volume":"55","author":"Rademaker","year":"2016","journal-title":"Int J Dermatol"},{"issue":"12","key":"dbr240007r10","doi-asserted-by":"publisher","first-page":"1392","DOI":"10.1001\/jamadermatol.2013.6746","article-title":"High-dose isotretinoin treatment and the rate of retrial, relapse, and adverse effects in patients with acne vulgaris.","volume":"149","author":"Blasiak","year":"2013","journal-title":"JAMA Dermatol"},{"issue":"2","key":"dbr240007r11","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1001\/jamadermatol.2023.5355","article-title":"Lived experience of acne and acne treatment in transgender patients.","volume":"160","author":"Gold","year":"2024","journal-title":"JAMA Dermatol"},{"issue":"1","key":"dbr240007r12","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1001\/jamadermatol.2019.3270","article-title":"Isotretinoin, patient safety, and patient-centered care\u2014time to reform iPLEDGE.","volume":"156","author":"Barbieri","year":"2020","journal-title":"JAMA Dermatol"},{"issue":"1","key":"dbr240007r13","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.jaad.2019.06.025","article-title":"The clinical utility of laboratory monitoring during isotretinoin therapy for acne and changes to monitoring practices over time.","volume":"82","author":"Barbieri","year":"2020","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"dbr240007r14","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1016\/j.jaad.2022.10.031","article-title":"Isotretinoin and the risk of psychiatric disturbances: a global study shedding new light on a debatable story.","volume":"88","author":"Kridin","year":"2023","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"dbr240007r15","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1089\/trgh.2019.0029","article-title":"Mental health diagnoses among transgender patients in the clinical setting: an all-payer electronic health record study.","volume":"4","author":"Wanta","year":"2019","journal-title":"Transgend Health"},{"key":"dbr240007r1","unstructured":"Herman? JL, Flores? AR, O\u2019Neill? KK. How many adults identify as transgender in the United States? Accessed April 26, 2024. https:\/\/williamsinstitute.law.ucla.edu\/wp-content\/uploads\/Trans-Pop-Update-Jun-2022.pdf"}],"container-title":["JAMA Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamadermatology\/articlepdf\/2819418\/jamadermatology_choe_2024_br_240007_1721149734.58201.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,17]],"date-time":"2024-07-17T15:02:28Z","timestamp":1721228548000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamadermatology\/fullarticle\/2819418"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,1]]},"references-count":15,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2024,7,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamadermatol.2024.1420","relation":{},"ISSN":["2168-6068"],"issn-type":[{"value":"2168-6068","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7,1]]}}}